Importantly, these responses were not only seen in patients with BRAFV600E but also in BRAFV600K and BRAFV600G mutations, and possibly shows the wider range of activity of selective BRAF inhibitors that are not limited only to BRAFV600E-mutant tumours. Here, BRAF is linked to neoplasm.